-
1
-
-
70349952103
-
Prostatespecific antigen-based screening for prostate cancer in the third millennium: Useful or hype
-
Lippi G, Montagnana M, Guidi GC, Plebani M. Prostatespecific antigen-based screening for prostate cancer in the third millennium: useful or hype Ann Med 2009;41: 480-9.
-
(2009)
Ann Med
, vol.41
, pp. 480-489
-
-
Lippi, G.1
Montagnana, M.2
Guidi, G.C.3
Plebani, M.4
-
2
-
-
0032550630
-
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
-
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Assoc 1998;279:1542-7.
-
(1998)
J Am Med Assoc
, vol.279
, pp. 1542-1547
-
-
Catalona, W.J.1
Partin, A.W.2
Slawin, K.M.3
Brawer, M.K.4
Flanigan, R.C.5
Patel, A.6
-
3
-
-
0037014792
-
Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. Prostate cancer incidence trends
-
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Nat Cancer Inst 2002;94:981-90.
-
(2002)
J Nat Cancer Inst
, vol.94
, pp. 981-990
-
-
Etzioni, R.1
Penson, D.F.2
Legler, J.M.3
Di Tommaso, D.4
Boer, R.5
Gann, P.H.6
-
4
-
-
2642548279
-
Natural history of early, localized prostate cancer
-
Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. J Am Med Assoc 2004;291:2713-9.
-
(2004)
J Am Med Assoc
, vol.291
, pp. 2713-2719
-
-
Johansson, J.E.1
Andrén, O.2
Andersson, S.O.3
Dickman, P.W.4
Holmberg, L.5
Magnuson, A.6
-
5
-
-
84882246985
-
PSA PCA3 and the philosophy of prostate cancer management
-
Melichar B. PSA, PCA3 and the philosophy of prostate cancer management. Clin Chem Lab Med 2013;51:707-12.
-
(2013)
Clin Chem Lab Med
, vol.51
, pp. 707-712
-
-
Melichar, B.1
-
6
-
-
84868707366
-
Kallikrein-related peptidases (KLKs): A gene family of novel cancer biomarkers
-
Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med 2012;50:1877-91.
-
(2012)
Clin Chem Lab Med
, vol.50
, pp. 1877-1891
-
-
Kontos, C.K.1
Scorilas, A.2
-
8
-
-
0033429470
-
DD3: A new prostate-specific gene, highly overexpressed in prostate cancer
-
Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.
-
(1999)
Cancer Res
, vol.59
, pp. 5975-5979
-
-
Bussemakers, M.J.1
Van Bokhoven, A.2
Verhaegh, G.W.3
Smit, F.P.4
Karthaus, H.F.5
Schalken, J.A.6
-
9
-
-
63449087026
-
New genomic structure for prostate cancer specific gene PCA3 within BMCC1: Implications for prostate cancer detection and progression
-
Clarke RA, Zhao Z, Guo AY, Roper K, Teng L, Fang ZM, et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 2009;4:e4995.
-
(2009)
PLoS One
, vol.4
, pp. e4995
-
-
Clarke, R.A.1
Zhao, Z.2
Guo, A.Y.3
Roper, K.4
Teng, L.5
Fang, Z.M.6
-
10
-
-
84857044547
-
Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion
-
Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 2012;187:795-801.
-
(2012)
J Urol
, vol.187
, pp. 795-801
-
-
Salagierski, M.1
Schalken, J.A.2
-
11
-
-
84868266739
-
PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling
-
Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer 2012;12:507.
-
(2012)
BMC Cancer
, vol.12
, pp. 507
-
-
Ferreira, L.B.1
Palumbo, A.2
De Mello, K.D.3
Sternberg, C.4
Caetano, M.S.5
De Oliveira, F.L.6
-
12
-
-
0037974513
-
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer
-
Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
-
(2003)
Eur Urol
, vol.44
, pp. 8-15
-
-
Hessels, D.1
Klein Gunnewiek, J.M.2
Van Oort, I.3
Karthaus, H.F.4
Van Leenders, G.J.5
Van Balken, B.6
-
13
-
-
2342452144
-
UPM3, a new molecular urine test for the detection of prostate cancer
-
Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-5.
-
(2004)
Urology
, vol.64
, pp. 311-315
-
-
Fradet, Y.1
Saad, F.2
Aprikian, A.3
Dessureault, J.4
Elhilali, M.5
Trudel, C.6
-
14
-
-
3142540904
-
DD3PCA3 RNA analysis in urine-new perspective for detecting prostate cancer
-
Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine-new perspective for detecting prostate cancer. Eur Urol 2004;46:182-6.
-
(2004)
Eur Urol
, vol.46
, pp. 182-186
-
-
Tinzl, M.1
Marberger, M.2
Horvath, S.3
Chypre, C.4
-
15
-
-
33646942410
-
APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
-
Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95.
-
(2006)
Clin Chem
, vol.52
, pp. 1089-1095
-
-
Groskopf, J.1
Aubin, S.M.2
Deras, I.L.3
Blase, A.4
Bodrug, S.5
Clark, C.6
-
16
-
-
77954516110
-
Assessment of the PCA3 test for prostate cancer diagnosis: A systematic review and metaanalysis
-
Ruiz-Aragón J, Márquez-Pelaéz S. Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and metaanalysis. Actas Urol Esp 2010;34:346-55.
-
(2010)
Actas Urol Esp
, vol.34
, pp. 346-355
-
-
Ruiz-Aragón, J.1
Márquez-Pelaéz, S.2
-
17
-
-
84880046360
-
Comparative effectiveness review: Prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer
-
Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 2013;190:389-98.
-
(2013)
J Urol
, vol.190
, pp. 389-398
-
-
Bradley, L.A.1
Palomaki, G.E.2
Gutman, S.3
Samson, D.4
Aronson, N.5
-
18
-
-
84899750574
-
Prostate cancer antigen 3 test for prostate biopsy decision: A systematic review and meta analysis
-
Luo Y, Gou X, Huang P, Mou C. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis. Chin Med J 2014;127:1768-74.
-
(2014)
Chin Med J
, vol.127
, pp. 1768-1774
-
-
Luo, Y.1
Gou, X.2
Huang, P.3
Mou, C.4
-
19
-
-
84900493843
-
The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: A systematic review and meta-analysis
-
Luo Y, Gou X, Huang P, Mou C. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J Androl 2014;16:487-92.
-
(2014)
Asian J Androl
, vol.16
, pp. 487-492
-
-
Luo, Y.1
Gou, X.2
Huang, P.3
Mou, C.4
-
20
-
-
55649120679
-
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy
-
Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54:1081-8.
-
(2008)
Eur Urol
, vol.54
, pp. 1081-1088
-
-
Haese, A.1
Dela Taille, A.2
Van Poppel, H.3
Marberger, M.4
Stenzl, A.5
Mulders, P.F.6
-
21
-
-
84867396410
-
Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: A prospective study of 1962 cases
-
Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1962 cases. J Urol 2012;188:1726-31.
-
(2012)
J Urol
, vol.188
, pp. 1726-1731
-
-
Crawford, E.D.1
Rove, K.O.2
Trabulsi, E.J.3
Qian, J.4
Drewnowska, K.P.5
Kaminetsky, J.C.6
-
22
-
-
84890020831
-
PCA3 score of 20 could improve prostate cancer detection: Results obtained on 734 Italian individuals
-
Capoluongo E, Zambon CF, Basso D, Boccia S, Rocchetti S, Leoncini E, et al. PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals. Clin Chim Acta 2014;429:46-50.
-
(2014)
Clin Chim Acta
, vol.429
, pp. 46-50
-
-
Capoluongo, E.1
Zambon, C.F.2
Basso, D.3
Boccia, S.4
Rocchetti, S.5
Leoncini, E.6
-
23
-
-
84855921304
-
The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance
-
Van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, et al. The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance. BJU Int 2012;109: 360-6.
-
(2012)
BJU Int
, vol.109
, pp. 360-366
-
-
Van Poppel, H.1
Haese, A.2
Graefen, M.3
Dela Taille, A.4
Irani, J.5
De Reijke, T.6
-
24
-
-
84862302363
-
The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy
-
Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012;110:43-9.
-
(2012)
BJU Int
, vol.110
, pp. 43-49
-
-
Durand, X.1
Xylinas, E.2
Radulescu, C.3
Haus-Cheymol, R.4
Moutereau, S.5
Ploussard, G.6
-
25
-
-
72849117496
-
Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer
-
Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010;70:10-6.
-
(2010)
Prostate
, vol.70
, pp. 10-16
-
-
Hessels, D.1
Van Gils, M.P.2
Van Hooij, O.3
Jannink, S.A.4
Witjes, J.A.5
Verhaegh, G.W.6
-
26
-
-
79551478699
-
Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance
-
Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011;59:422-9.
-
(2011)
Eur Urol
, vol.59
, pp. 422-429
-
-
Ploussard, G.1
Durand, X.2
Xylinas, E.3
Moutereau, S.4
Radulescu, C.5
Forgue, A.6
-
27
-
-
48749090994
-
Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results
-
van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008;68:1215-22.
-
(2008)
Prostate
, vol.68
, pp. 1215-1222
-
-
Van Gils, M.P.1
Hessels, D.2
Hulsbergen-Vande Kaa, C.A.3
Witjes, J.A.4
Jansen, C.F.5
Mulders, P.F.6
-
28
-
-
84900403208
-
Urinary PCA3 as a predictor for prostate cancer in a cohort of 3073 men undergoing initial prostate biopsy
-
Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A, et al. Urinary PCA3 as a predictor for prostate cancer in a cohort of 3073 men undergoing initial prostate biopsy. J Urol 2014;191:1743-8.
-
(2014)
J Urol
, vol.191
, pp. 1743-1748
-
-
Chevli, K.K.1
Duff, M.2
Walter, P.3
Yu, C.4
Capuder, B.5
Elshafei, A.6
-
29
-
-
84901044470
-
Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection
-
Foj L, Milà M, Mengual L, Luque P, Alcaraz A, Jiménez W, et al. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clin Chim Acta 2014;435: 53-8.
-
(2014)
Clin Chim Acta
, vol.435
, pp. 53-58
-
-
Foj, L.1
Milà, M.2
Mengual, L.3
Luque, P.4
Alcaraz, A.5
Jiménez, W.6
-
30
-
-
78049478702
-
Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: Reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores ( 100)
-
Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores ( 100). Eur Urol 2010;58:893-9.
-
(2010)
Eur Urol
, vol.58
, pp. 893-899
-
-
Roobol, M.J.1
Schröder, F.H.2
Van Leenders, G.L.3
Hessels, D.4
Van Den Bergh, R.C.5
Wolters, T.6
-
31
-
-
84896867550
-
Prostate cancer antigen 3: Diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores 100
-
Schröder FH, Venderbos LD, van den Bergh RC, Hessels D, van Leenders GJ, van Leeuwen PJ, et al. Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores 100. Urology 2014;83:613-6.
-
(2014)
Urology
, vol.83
, pp. 613-616
-
-
Schröder, F.H.1
Venderbos, L.D.2
Vanden Bergh, R.C.3
Hessels, D.4
Van Leenders, G.J.5
Van Leeuwen, P.J.6
-
32
-
-
0029642254
-
Clinical usefulness of free PSA fraction as an indicator of prostate cancer
-
Filella X, Alcover J, Molina R, Giménez N, Rodríguez A, Jo J, et al. Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int J Cancer 1995;63:780-4.
-
(1995)
Int J Cancer
, vol.63
, pp. 780-784
-
-
Filella, X.1
Alcover, J.2
Molina, R.3
Giménez, N.4
Rodríguez, A.5
Jo, J.6
-
33
-
-
23944492852
-
Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis
-
Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
-
(2005)
Eur Urol
, vol.48
, pp. 386-399
-
-
Roddam, A.W.1
Duffy, M.J.2
Hamdy, F.C.3
Ward, A.M.4
Patnick, J.5
Price, C.P.6
-
34
-
-
33646009994
-
A meta-analysis of the performance characteristics of the free prostate-specific antigen test
-
free PSA study group
-
Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS, free PSA study group. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006;67:762-8.
-
(2006)
Urology
, vol.67
, pp. 762-768
-
-
Lee, R.1
Localio, A.R.2
Armstrong, K.3
Malkowicz, S.B.4
Schwartz, J.S.5
-
36
-
-
0035884510
-
A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer
-
Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958-63.
-
(2001)
Cancer Res
, vol.61
, pp. 6958-6963
-
-
Mikolajczyk, S.D.1
Marker, K.M.2
Millar, L.S.3
Kumar, A.4
Saedi, M.S.5
Payne, J.K.6
-
37
-
-
84878446009
-
Evaluation of [-2] proPSA and Prostate Health Index (PHI) for the detection of prostate cancer: A systematic review and meta-analysis
-
Filella X, Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (PHI) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729-39.
-
(2013)
Clin Chem Lab Med
, vol.51
, pp. 729-739
-
-
Filella, X.1
Giménez, N.2
-
38
-
-
84901400634
-
Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: A meta-analysis
-
Wang W, Wang M, Wang L, Adams TS, Tian Y, Xu J. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis. Sci Rep 2014;4:5012.
-
(2014)
Sci Rep
, vol.4
, pp. 5012
-
-
Wang, W.1
Wang, M.2
Wang, L.3
Adams, T.S.4
Tian, Y.5
Xu, J.6
-
39
-
-
84872013934
-
Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer
-
Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2013;59:306-14.
-
(2013)
Clin Chem
, vol.59
, pp. 306-314
-
-
Stephan, C.1
Vincendeau, S.2
Houlgatte, A.3
Cammann, H.4
Jung, K.5
Semjonow, A.6
-
40
-
-
84876473108
-
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: A multicentric European study
-
Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013;63:986-94.
-
(2013)
Eur Urol
, vol.63
, pp. 986-994
-
-
Lazzeri, M.1
Haese, A.2
De La Taille, A.3
Palou Redorta, J.4
McNicholas, T.5
Lughezzani, G.6
-
41
-
-
84904052047
-
Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer
-
Filella X, Foj L, Augé JM, Molina R, Alcover J. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clin Chem Lab Med 2014;52:1347-55.
-
(2014)
Clin Chem Lab Med
, vol.52
, pp. 1347-1355
-
-
Filella, X.1
Foj, L.2
Augé, J.M.3
Molina, R.4
Alcover, J.5
-
42
-
-
77952082471
-
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness
-
Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193-200.
-
(2010)
Cancer Epidemiol Biomarkers Prev
, vol.19
, pp. 1193-1200
-
-
Sokoll, L.J.1
Sanda, M.G.2
Feng, Z.3
Kagan, J.4
Mizrahi, I.A.5
Broyles, D.L.6
-
43
-
-
58849091840
-
A [-2] proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases
-
Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009;69:198-207.
-
(2009)
Prostate
, vol.69
, pp. 198-207
-
-
Stephan, C.1
Kahrs, A.M.2
Cammann, H.3
Lein, M.4
Schrader, M.5
Deger, S.6
-
44
-
-
79959554692
-
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting
-
Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011;60:214-22.
-
(2011)
Eur Urol
, vol.60
, pp. 214-222
-
-
Guazzoni, G.1
Nava, L.2
Lazzeri, M.3
Scattoni, V.4
Lughezzani, G.5
MacCagnano, C.6
-
45
-
-
84909963352
-
Multicenter european external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy
-
Lughezzani G, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, et al. Multicenter european external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol 2014;66:906-12.
-
(2014)
Eur Urol
, vol.66
, pp. 906-912
-
-
Lughezzani, G.1
Lazzeri, M.2
Haese, A.3
McNicholas, T.4
Dela Taille, A.5
Buffi, N.M.6
-
46
-
-
84904044333
-
The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 g/L
-
Filella X, Foj L, Alcover J, Augé JM, Molina R, Jiménez W. The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 g/L. Clin Chim Acta 2014;436:303-7.
-
(2014)
Clin Chim Acta
, vol.436
, pp. 303-307
-
-
Filella, X.1
Foj, L.2
Alcover, J.3
Augé, J.M.4
Molina, R.5
Jiménez, W.6
-
47
-
-
80054735054
-
Budget impact analysis of a new prostate cancer risk index for prostate cancer detection
-
Nichol MB, Wu J, An JJ, Huang J, Denham D, Frencher S, et al. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. Prostate Cancer Prostatic Dis 2011;14:253-61.
-
(2011)
Prostate Cancer Prostatic Dis
, vol.14
, pp. 253-261
-
-
Nichol, M.B.1
Wu, J.2
An, J.J.3
Huang, J.4
Denham, D.5
Frencher, S.6
-
48
-
-
84863719857
-
Cost-effectiveness of Prostate Health Index for prostate cancer detection
-
Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ. Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU Int 2011;110:353-62.
-
(2011)
BJU Int
, vol.110
, pp. 353-362
-
-
Nichol, M.B.1
Wu, J.2
Huang, J.3
Denham, D.4
Frencher, S.K.5
Jacobsen, S.J.6
-
49
-
-
77951621115
-
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection
-
Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7.
-
(2010)
Eur Urol
, vol.57
, pp. 921-927
-
-
Jansen, F.H.1
Van Schaik, R.H.2
Kurstjens, J.3
Horninger, W.4
Klocker, H.5
Bektic, J.6
-
50
-
-
84866090485
-
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer
-
Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, et al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012;188:1131-6.
-
(2012)
J Urol
, vol.188
, pp. 1131-1136
-
-
Tosoian, J.J.1
Loeb, S.2
Feng, Z.3
Isharwal, S.4
Landis, P.5
Elliot, D.J.6
-
51
-
-
3042681119
-
Are multiple markers the future of prostate cancer diagnostics
-
Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG. Are multiple markers the future of prostate cancer diagnostics Clin Biochem 2004;37:519-28.
-
(2004)
Clin Biochem
, vol.37
, pp. 519-528
-
-
Mikolajczyk, S.D.1
Song, Y.2
Wong, J.R.3
Matson, R.S.4
Rittenhouse, H.G.5
-
52
-
-
84866112632
-
Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy
-
Lughezzani G, Lazzeri M, Larcher A, Lista G, Scattoni V, Cestari A, et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 2012;188:1144-50.
-
(2012)
J Urol
, vol.188
, pp. 1144-1150
-
-
Lughezzani, G.1
Lazzeri, M.2
Larcher, A.3
Lista, G.4
Scattoni, V.5
Cestari, A.6
-
53
-
-
0035018273
-
The new human tissue kallikrein gene family: Structure, function, and association to disease
-
Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204.
-
(2001)
Endocr Rev
, vol.22
, pp. 184-204
-
-
Yousef, G.M.1
Diamandis, E.P.2
-
54
-
-
0031024041
-
Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors
-
Tremblay RR, Deperthes D, Tetu B, Dube JY. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol 1997;150:455-9.
-
(1997)
Am J Pathol
, vol.150
, pp. 455-459
-
-
Tremblay, R.R.1
Deperthes, D.2
Tetu, B.3
Dube, J.Y.4
-
55
-
-
0032721585
-
Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis
-
Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999;54:839-45.
-
(1999)
Urology
, vol.54
, pp. 839-845
-
-
Partin, A.W.1
Catalona, W.J.2
Finlay, J.A.3
Darte, C.4
Tindall, D.J.5
Young, C.Y.6
-
56
-
-
17744400811
-
In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic gray zone" of total PSA 4 to 10 ng/mL
-
Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998;52:360-5.
-
(1998)
Urology
, vol.52
, pp. 360-365
-
-
Kwiatkowski, M.K.1
Recker, F.2
Piironen, T.3
Pettersson, K.4
Otto, T.5
Wernli, M.6
-
57
-
-
24044527859
-
Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection
-
Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, et al. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 2005;96:521-7.
-
(2005)
BJU Int
, vol.96
, pp. 521-527
-
-
Stephan, C.1
Jung, K.2
Soosaipillai, A.3
Yousef, G.M.4
Cammann, H.5
Meyer, H.6
-
58
-
-
33645458299
-
Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer
-
Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 2006;13:238-43.
-
(2006)
Int J Urol
, vol.13
, pp. 238-243
-
-
Stephan, C.1
Jung, K.2
Nakamura, T.3
Yousef, G.M.4
Kristiansen, G.5
Diamandis, E.P.6
-
59
-
-
0034007660
-
Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer
-
Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H, et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol 2000;163:1491-7.
-
(2000)
J Urol
, vol.163
, pp. 1491-1497
-
-
Haese, A.1
Becker, C.2
Noldus, J.3
Graefen, M.4
Huland, E.5
Huland, H.6
-
60
-
-
0034791830
-
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml
-
Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49:101-9.
-
(2001)
Prostate
, vol.49
, pp. 101-109
-
-
Haese, A.1
Graefen, M.2
Steuber, T.3
Becker, C.4
Pettersson, K.5
Piironen, T.6
-
61
-
-
48249152185
-
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg Sweden
-
Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med 2008;6:19.
-
(2008)
BMC Med
, vol.6
, pp. 19
-
-
Vickers, A.J.1
Cronin, A.M.2
Aus, G.3
Pihl, C.G.4
Becker, C.5
Pettersson, K.6
-
62
-
-
77953688557
-
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication
-
Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010;28:2493-8.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2493-2498
-
-
Vickers, A.1
Cronin, A.2
Roobol, M.3
Savage, C.4
Peltola, M.5
Pettersson, K.6
-
63
-
-
77953715079
-
A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European Randomized Study of Screening for Prostate Cancer Rotterdam
-
Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010;16:3232-9.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3232-3239
-
-
Vickers, A.J.1
Cronin, A.M.2
Roobol, M.J.3
Savage, C.J.4
Peltola, M.5
Pettersson, K.6
-
64
-
-
77952800766
-
Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostatespecific antigen: Data from the European Randomized Study of Prostate Cancer Screening in Gothenburg
-
Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostatespecific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010;116:2612-20.
-
(2010)
Sweden. Cancer
, vol.116
, pp. 2612-2620
-
-
Vickers, A.J.1
Cronin, A.M.2
Aus, G.3
Pihl, C.G.4
Becker, C.5
Pettersson, K.6
-
65
-
-
77955981143
-
A four-kallikrein panel for the prediction of repeat prostate biopsy: Data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands
-
Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer 2010;103:708-14.
-
(2010)
Br J Cancer
, vol.103
, pp. 708-714
-
-
Gupta, A.1
Roobol, M.J.2
Savage, C.J.3
Peltola, M.4
Pettersson, K.5
Scardino, P.T.6
-
66
-
-
78549255938
-
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: An independent validation study from the European Randomized Study of Prostate Cancer screening France
-
Benchikh A, Savage C, Cronin A, Salama G, Villers A, Lilja H, et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010;10:635.
-
(2010)
BMC Cancer
, vol.10
, pp. 635
-
-
Benchikh, A.1
Savage, C.2
Cronin, A.3
Salama, G.4
Villers, A.5
Lilja, H.6
-
67
-
-
79951626849
-
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening
-
Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011;20:255-61.
-
(2011)
Cancer Epidemiol Biomarkers Prev
, vol.20
, pp. 255-261
-
-
Vickers, A.J.1
Gupta, A.2
Savage, C.J.3
Pettersson, K.4
Dahlin, A.5
Bjartell, A.6
-
68
-
-
84885434644
-
Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: Results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam
-
Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T, et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur Urol 2013;64:693-9.
-
(2013)
Eur Urol
, vol.64
, pp. 693-699
-
-
Carlsson, S.1
Maschino, A.2
Schröder, F.3
Bangma, C.4
Steyerberg, E.W.5
Van Der Kwast, T.6
-
69
-
-
84930814511
-
Improving the specificity of prostate cancer screening for early detection of lethal disease
-
Lilja H, Vickers AJ, Sjoberg D, Johansson R, Granfors T, Johansson M, et al. Improving the specificity of prostate cancer screening for early detection of lethal disease. J Clin Oncol 2014;32:5s [abstr 5081].
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Lilja, H.1
Vickers, A.J.2
Sjoberg, D.3
Johansson, R.4
Granfors, T.5
Johansson, M.6
-
70
-
-
84892435339
-
The Kallikrein Panel for prostate cancer screening: Its economic impact
-
Voigt JD, Zappala SM, Vaughan ED, Wein AJ. The Kallikrein Panel for prostate cancer screening: its economic impact. Prostate 2014;74:250-9.
-
(2014)
Prostate
, vol.74
, pp. 250-259
-
-
Voigt, J.D.1
Zappala, S.M.2
Vaughan, E.D.3
Wein, A.J.4
-
71
-
-
84940603595
-
A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer
-
Oct 27. pii: S0302-2838(14) 01035-5
-
Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, et al. A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. Eur Urol. 2014 Oct 27. pii: S0302-2838(14)01035-5. doi: 10.1016/j.eururo.2014.10.021.
-
(2014)
Eur Urol.
-
-
Parekh, D.J.1
Punnen, S.2
Sjoberg, D.D.3
Asroff, S.W.4
Bailen, J.L.5
Cochran, J.S.6
-
72
-
-
81855206806
-
Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force
-
Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71.
-
(2011)
Ann Intern Med
, vol.155
, pp. 762-771
-
-
Chou, R.1
Croswell, J.M.2
Dana, T.3
Bougatsos, C.4
Blazina, I.5
Fu, R.6
-
73
-
-
84883037091
-
Prostate-specific antigen and prostate cancer mortality: A systematic review
-
Wallner LP, Jacobsen SJ. Prostate-specific antigen and prostate cancer mortality: a systematic review. Am J Prev Med 2013;45:318-26.
-
(2013)
Am J Prev Med
, vol.45
, pp. 318-326
-
-
Wallner, L.P.1
Jacobsen, S.J.2
-
74
-
-
79952133146
-
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50
-
Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011;117:1210-9.
-
(2011)
Cancer
, vol.117
, pp. 1210-1219
-
-
Lilja, H.1
Cronin, A.M.2
Dahlin, A.3
Manjer, J.4
Nilsson, P.M.5
Eastham, J.A.6
-
75
-
-
84888815889
-
EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013
-
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37.
-
(2014)
Eur Urol
, vol.65
, pp. 124-137
-
-
Heidenreich, A.1
Bastian, P.J.2
Bellmunt, J.3
Bolla, M.4
Joniau, S.5
Van Der Kwast, T.6
-
76
-
-
84872033007
-
Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2] proprostate-specific antigen-based prostate health index for detection of prostate cancer
-
Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2] proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013;59:280-8.
-
(2013)
Clin Chem
, vol.59
, pp. 280-288
-
-
Stephan, C.1
Jung, K.2
Semjonow, A.3
Schulze-Forster, K.4
Cammann, H.5
Hu, X.6
-
77
-
-
84880046442
-
Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy
-
Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E, et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013;190:496-501.
-
(2013)
J Urol
, vol.190
, pp. 496-501
-
-
Scattoni, V.1
Lazzeri, M.2
Lughezzani, G.3
De Luca, S.4
Passera, R.5
Bollito, E.6
-
78
-
-
84905241494
-
Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness
-
Tallon L, Luangphakdy D, Ruffion A, Colombel M, Devonec M, Champetier D, et al. Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness. Int J Mol Sci 2014;15:13299-316.
-
(2014)
Int J Mol Sci
, vol.15
, pp. 13299-13316
-
-
Tallon, L.1
Luangphakdy, D.2
Ruffion, A.3
Colombel, M.4
Devonec, M.5
Champetier, D.6
-
79
-
-
84942991529
-
Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer
-
Aug 20. pii: S0302-2838(14) 00752-0.
-
Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2014 Aug 20. pii: S0302-2838(14)00752-0. doi: 10.1016/j.eururo.2014.08.010.
-
(2014)
Eur Urol
-
-
Nordström, T.1
Vickers, A.2
Assel, M.3
Lilja, H.4
Grönberg, H.5
Eklund, M.6
-
80
-
-
84910080750
-
The added value of percentage of free to total prostate-specific antigen PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men
-
Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, et al. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol 2014;66:1109-15.
-
(2014)
Eur Urol
, vol.66
, pp. 1109-1115
-
-
Vedder, M.M.1
De Bekker-Grob, E.W.2
Lilja, H.G.3
Vickers, A.J.4
Van Leenders, G.J.5
Steyerberg, E.W.6
|